Elixirgen Therapeutics raised $8.2 million toward developing therapies using ZSCAN4 to extend telomeres in stem cells for patients with Telomere Biology Disorders, a rare disease, and is also advancing its Bobcat mRNA technology to deliver large therapeutic genes, including full-length dystrophin for Duchenne muscular dystrophy.
